2-Part Webinar-Series: Driving Precision in Breast Cancer Care

Discover how leadership and teamwork shape the future of breast cancer treatment and surveillance.

Part 2: Optimizing Breast Cancer Surveillance: A team approach with MRD testing

Date: Thursday, October 16, 2025

Time: 3:00 PM PT | 6:00 PM ET

Duration: 60 minutes

Registrants will receive a recording of the webinar approximately one week after the event.

In part 2 of this webinar-series, learn how surveillance strategies are evolving rapidly with the integration of Signatera™ MRD testing. This session will focus on how collaboration and MRD testing are reshaping follow-up care and improving patient outcomes.

This webinar will highlight:

How MRD testing can inform follow-up and surveillance strategies
Practical approaches to integrating MRD into ongoing patient care
Case-based discussion of MRD-informed surveillance decisions
The collaborative role of surgeons and oncologists in post-treatment monitoring

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers

Barry S. Rosen, MD, FACS

Dr. Rosen is a nationally recognized breast surgical oncologist with more than 30 years of experience. A leader in oncoplastic techniques and breast cancer quality initiatives, he has served in senior hospital leadership roles and also advises on cancer innovation. He is active in the American Society of Breast Surgeons and dedicates his time to help shape precision cancer care.

Sandeep Chunduri, MD

Dr. Chunduri is a board-certified hematologist–oncologist with more than two decades of experience in community-based cancer care. Practicing with Advocate Health in Illinois, he focuses on the management of breast and other solid tumors, bringing deep expertise in systemic therapy and multidisciplinary care. He is recognized for his collaborative approach with surgeons and radiation oncologists to ensure patients benefit from precision treatment strategies.

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2025 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy